Status:
UNKNOWN
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
60-75 years
Phase:
PHASE2
Brief Summary
This is an open-label, single arm, phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with DNA methyltransferase inhibitor decitabine in elderly patients wi...
Detailed Description
In this single-center, open-label, nonrandomized, no control, prospective clinical trial, 29 relapsed or refractory acute myeloid leukemia patients will be enrolled. Patients will be administered Camr...
Eligibility Criteria
Inclusion
- Age: 60-75
- Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology
- ECOG：0-2
- Life expectancy ≥ 3 months
- Adequate laboratory parameters during the screening period as evidenced by the following:
- Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L
- ALT and AST ≤ 3 × upper limit of normal (ULN)
- FEV1,FVC,DLCO ≥ 50% predicted value
- Left ventricular ejection fraction (LVEF) ≥ 40%, no symptomatic arrhythmia
- Able to understand and sign an informed consent form (ICF).
Exclusion
- Treatment-related AML
- Allergic to Camrelizumab, Decitabine, other monoclonal antibody or pharmaceutical excipients
- Use of immunosuppressive drug within 2 weeks before entering the group
- Abnormal liver and kidney function(does not meet the inclusion criteria)
- Suffering from heart failure
- Active tuberculosis or HIV positive
- Active hepatitis: Hepatitis B(HBsAg positive and HBV DNA≥500IU/mL), and hepatitis C(HCV RNA positive, abnormal liver function) ,Hepatitis B and hepatitis C infection in common.
- Active, known or suspected autoimmune disease. Subjects who were in a stable state without systemic immunosuppressive therapy were admitted
- Concurrent medical condition requiring the long-term use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids \> 10 mg/day topical prednisone or equivalent
- Suffer from other hematological neoplasm
- Known history of use other immune checkpoint inhibitor
- Other factors that may lead to the study termination, such as severe disease or abnormal laboratory tests or family or social factors affecting subjects safety or test data and sample collection.
Key Trial Info
Start Date :
April 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04353479
Start Date
April 25 2020
End Date
December 31 2022
Last Update
April 20 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.